Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
20. Dezember 2024 09:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative...
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
05. Dezember 2024 16:21 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
03. Dezember 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
08. November 2024 08:00 ET
|
Monopar Therapeutics Inc.
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid...
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
30. Oktober 2024 13:42 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
28. Oktober 2024 21:15 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
28. Oktober 2024 16:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
24. Oktober 2024 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
22. Oktober 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
15. Oktober 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...